RTI Biologics, Inc. (RTIX) Tops Q2 EPS by 1c

RTI Biologics, Inc. (NASDAQ: RTIX) reported Q2 EPS of $0.03, $0.01 better than the analyst estimate of $0.02. Revenue for the quarter came in at $66 million versus the consensus estimate of $59.2 million.

“We are extremely pleased with our results from the second quarter. Revenues exceeded our expectations and signify, in our opinion, that our business has not only stabilized but has momentum moving into the second half of the year,” said Brian K. Hutchison, president and chief executive officer. “We made progress in meeting the goals we shared in our first quarter earnings press release - recovery and growth in our sports and spine businesses, traction in surgical specialties and expanded distribution of map3 cellular allogeneic bone graft.”

For earnings history and earnings-related data on RTI Biologics, Inc. (RTIX) click here.

You May Also Be Interested In

• JPMorgan Upgrades Aviva Plc (AV/:LN) (AIVAF) to Overweight
• Bluejay Diagnostics completes enrollment in IL-6 pivotal study
• 22nd Century Group (XXII) Misses Q2 EPS by 9800c